Borage Oil (GLA).

GLA is elongated to DGLA, and EPA slows the delta-5 desaturase step that would carry DGLA onward to arachidonic acid. Pairing the two keeps more of the GLA load sitting at DGLA, which is the series-1 eicosanoid arm.

Linoleic acid is the dietary precursor and GLA is its immediate delta-6 desaturase product. Supplying GLA directly steps past the slowest point in that conversion.

Borage oil is highly unsaturated and oxidises readily in the softgel and in tissue lipids. Tocopherol is the chain-breaking antioxidant that keeps the fatty acid intact.

Ascorbate regenerates the tocopheroxyl radical back to active vitamin E at the lipid and water boundary. That recycling loop is what lets a small amount of vitamin E protect a large pool of polyunsaturated oil.

Delta-6 desaturase activity depends on adequate zinc status. Low zinc slows the body's own conversion of linoleic acid, which is part of why a preformed GLA oil is used at all.

Fat-soluble vitamins need dietary lipid to form mixed micelles in the small intestine. A GLA softgel taken alongside supplies that lipid and raises uptake of the vitamin.

Astaxanthin is a carotenoid that absorbs far better when taken with an oil. It also sits in the membrane lipid phase and slows peroxidation of the polyunsaturated fatty acid it travelled in with.

DGLA derived from GLA feeds prostaglandin E1, which lowers normal platelet aggregation, while ginkgolides antagonise platelet activating factor. The two effects add up on the same physiology and the combination deserves a flag.

Garlic organosulfur compounds reduce normal platelet aggregation by their own route. Stacked with the prostaglandin E1 arm that GLA feeds, the effect on clotting is additive.

Nattokinase acts on the fibrin side of normal clot handling. Combined with a GLA oil that lowers platelet aggregation, the two work on the same end point from different directions.

The delta-6 desaturase step that starts the conversion of linoleic acid to gamma-linolenic acid depends on pyridoxine status, so B6 sits upstream of the pathway borage oil feeds. Borage oil supplies GLA already formed, which means it bypasses that bottleneck for its own molecule. The pairing matters when a formula also relies on dietary linoleic acid being converted. This is pathway biochemistry, not a tested combination.

Desaturase and elongase enzymes in the omega-6 chain are magnesium dependent, including the elongation of GLA to dihomo-gamma-linolenic acid. Adequate magnesium supports the normal handling of the fatty acid borage oil delivers. No combination trial is being cited here, only the cofactor requirement.

Biotin is the carboxylase cofactor in de novo fatty acid handling and has been described as a contributor to normal desaturase activity. The link to GLA specifically is inferred from shared pathway biochemistry rather than measured in a combination study, so it is held at a lower confidence.

GLA elongates to dihomo-gamma-linolenic acid, which can be converted onward to arachidonic acid; EPA competes at the same downstream enzymes and for the same acyl positions in membrane phospholipids. Formulators pair the two so the omega-6 intermediate accumulates without pushing the arachidonic branch. The interaction is competitive at the enzyme level and additive at the formulation level, which is why polarity here is modulating.

DHA occupies membrane phospholipid positions that would otherwise carry omega-6 derived chains, so it shifts the fatty acid balance a GLA source moves in the other direction. Both are long-chain polyunsaturated fatty acids handled by the same incorporation machinery. Pairing is a balance decision, not an enhancement of GLA itself.

Alpha-linolenic acid from flaxseed and linoleic acid both need delta-6 desaturase, the same enzyme that makes GLA endogenously. Adding a large alpha-linolenic load competes for that step. Since borage oil supplies GLA directly, the competition affects the rest of the pathway rather than the borage-derived molecule.

Both oils are GLA sources; borage seed oil typically carries a higher GLA share by weight than evening primrose oil, which is richer in linoleic acid. Those are compositional facts, not a reason to prefer one. Combining them raises total GLA intake without changing the mechanism, so the GLA total needs counting once rather than twice.

Borage oil is a triglyceride and needs pancreatic lipase to release its fatty acids before absorption. Where fat digestion is limited, supplemental lipase is the step that makes any oil available. This is standard digestive physiology.

Bile salts emulsify dietary oil into micelles, the form lipase can act on and the enterocyte can take up. Low bile output limits uptake of any seed oil. The pairing addresses the emulsification step rather than GLA metabolism.

Medium-chain triglycerides act as a carrier phase for long-chain oils in softgels and emulsions and are absorbed by a less bile-dependent route themselves. The role is vehicle and dispersion, not an increase in GLA conversion. Formulation practice, not a clinical finding.

Phospholipid emulsifiers keep an oil dispersed in emulsions and self-emulsifying systems, which is the same problem the polyol-free nanoemulsion work on borage oil addressed. Dispersion is a physical property, measured in the formulation rather than in a person.

Curcuminoids have a described mild effect on platelet aggregation, and polyunsaturated oils shift eicosanoid balance in the same direction. Stacked at high intakes the effects may add. Worth flagging on a label rather than presenting as a benefit.

Ginger constituents have been described as reducing platelet aggregation in laboratory work, and long-chain polyunsaturated fatty acids act on the same eicosanoid pathways. The additive direction is the reason to note the pair. Not grounded in a combination trial.

Salicylates from willow bark act on cyclooxygenase, the same enzyme family that handles the dihomo-gamma-linolenic acid derived from GLA. The overlap is mechanistic and the combined direction may be additive. Flagged for awareness, not proposed as an enhancement.

Vitamin K drives the gamma-carboxylation of clotting factors, which is a different step from the mild damping of platelet aggregation described for a polyunsaturated oil load. The two act on separate steps and no offsetting amount has been measured. Named so the combined picture is visible on a formula sheet.